1,112
Views
1
CrossRef citations to date
0
Altmetric
Review Article

Circulating neutrophil gelatinase-associated lipocalin and preeclampsia: a meta-analysis

, , , , &
Article: 2197100 | Received 20 Dec 2022, Accepted 26 Mar 2023, Published online: 06 Jun 2023

References

  • Nirupama R, Divyashree S, Janhavi P, et al. Preeclampsia: pathophysiology and management. J Gynecol Obstet Hum Reprod. 2021;50(2):101975.
  • Jung E, Romero R, Yeo L, et al. The etiology of preeclampsia. Am J Obstet Gynecol. 2022;226(2S):S844–S866.
  • Abalos E, Cuesta C, Grosso AL, et al. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1–7.
  • Bokslag A, van Weissenbruch M, Mol BW, et al. Preeclampsia; short and long-term consequences for mother and neonate. Early Hum Dev. 2016;102:47–50.
  • Turbeville HR, Sasser JM. Preeclampsia beyond pregnancy: long-term consequences for mother and child. Am J Physiol Renal Physiol. 2020;318(6):F1315–F1326.
  • Dennehy N, Lees C. Preeclampsia: maternal cardiovascular function and optimising outcomes. Early Hum Dev. 2022;174:105669.
  • Wu P, Haththotuwa R, Kwok CS, et al. Preeclampsia and future cardiovascular health: a systematic review and Meta-Analysis. Circ Cardiovasc Qual Outcomes. 2017;10(2): e003497.
  • Liu YH, Zhang YS, Chen JY, et al. Comparative effectiveness of prophylactic strategies for preeclampsia: a network meta-analysis of randomized controlled trials. Am J Obstet Gynecol. 2023;228(5):535–546.
  • Amaral LM, Wallace K, Owens M, et al. Pathophysiology and current clinical management of preeclampsia. Curr Hypertens Rep. 2017;19(8):61.
  • MacDonald TM, Walker SP, Hannan NJ, et al. Clinical tools and biomarkers to predict preeclampsia. EBioMedicine. 2022;75:103780.
  • Li D, Yan Sun W, Fu B, et al. Lipocalin-2-the myth of its expression and function. Basic Clin Pharmacol Toxicol. 2020;127(2):142–151.
  • Jaberi SA, Cohen A, D'Souza C, et al. Lipocalin-2: structure, function, distribution and role in metabolic disorders. Biomed Pharmacother. 2021;142:112002.
  • Zhao P, Elks CM, Stephens JM. The induction of lipocalin-2 protein expression in vivo and in vitro. J Biol Chem. 2014;289(9):5960–5969.
  • Araos P, Amador CA. Neutrophil gelatinase-associated lipocalin as an immunomodulator in endocrine hypertension. Front Endocrinol. 2022;13:1006790.
  • Bhusal A, Rahman MH, Lee WH, et al. Paradoxical role of lipocalin-2 in metabolic disorders and neurological complications. Biochem Pharmacol. 2019;169:113626.
  • Buonafine M, Martinez-Martinez E, Jaisser F. More than a simple biomarker: the role of NGAL in cardiovascular and renal diseases. Clin Sci. 2018;132(9):909–923.
  • Moschen AR, Adolph TE, Gerner RR, et al. Lipocalin-2: a master mediator of intestinal and metabolic inflammation. Trends Endocrinol Metab. 2017;28(5):388–397.
  • D'Anna R, Baviera G, Giordano D, et al. Second trimester neutrophil gelatinase-associated lipocalin as a potential prediagnostic marker of preeclampsia. Acta Obstet Gynecol Scand. 2008;87(12):1370–1373.
  • Youssef A, Righetti F, Morano D, et al. Uterine artery doppler and biochemical markers (PAPP-A, PIGF, sFlt-1, P-selectin, NGAL) at 11 + 0 to 13 + 6 weeks in the prediction of late (>34 weeks) pre-eclampsia. Prenat Diagn. 2011;31(12):1141–1146.
  • Cao WH, Chen WP, Li J, et al. Correlation of lipocalin-2 and its receptor expressions with preeclampsia. Zhonghua Fu Chan Ke Za Zhi. 2012;47(6):418–421.
  • Xiao J, Niu J, Ye X, et al. Combined biomarkers evaluation for diagnosing kidney injury in preeclampsia. Hypertens Pregnancy. 2013;32(4):439–449.
  • Karampas G, Eleftheriades M, Panoulis K, et al. Maternal serum levels of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in pregnancies with preeclampsia and those with a small for gestational age neonate: a longitudinal study. Prenat Diagn. 2014;34(8):726–733.
  • Sachan R, Patel M, Gaurav A, et al. Correlation of serum neutrophil gelatinase associated lipocalin with disease severity in hypertensive disorders of pregnancy. Adv Biomed Res. 2014;3(1):223.
  • Zhang HB, Fan JM, Zhu LL, et al. Combination of NGAL and cystatin C for prediction of preeclampsia at 10-14 weeks of gestation. Clin Lab. 2019;65(5). DOI:10.7754/Clin.Lab.2018.180831
  • Pihl K, Sørensen S, Stener Jørgensen F. Prediction of preeclampsia in nulliparous women according to first trimester maternal factors and serum markers. Fetal Diagn Ther. 2020;47(4):277–283.
  • Ali EA, Hameed BH, Salman AF. The value of neutrophil gelatinase-associated lipocalin and neutrophil/lymphocyte ratio in the diagnosis of preeclampsia and its severity. J Med Invest. 2021;68(3.4):321–325.
  • Li L, Ling B, Mei J, et al. Expression and significance of serum soluble fms-like tyrosine kinase 1 (sFlt-1), CXC chemokine ligand 16 (CXCL16), and lipocalin 2 (LCN-2) in pregnant women with preeclampsia. Ann Palliat Med. 2021;10(7):7866–7871.
  • Yalman MV, Madendag Y, Sahin E, et al. Effect of preeclampsia and its severity on maternal serum NGAL and KIM-1 levels during pregnancy and the post-pregnancy period. Eur J Obstet Gynecol Reprod Biol. 2021;256:246–251.
  • Parasher N, Kaushik P, Singh NK, et al. Association of neutrophil gelatinase associated lipocalin, ischemia modified albumin with uric acid in the etiopathogenesis of preeclampsia. Horm Mol Biol Clin Investig. 2022;44(1):39–43.
  • D'Anna R, Baviera G, Giordano D, et al. First trimester serum PAPP-A and NGAL in the prediction of late-onset pre-eclampsia. Prenat Diagn. 2009;29(11):1066–1068.
  • Stepan H, Philipp A, Reiche M, et al. Serum levels of the adipokine lipocalin-2 are increased in preeclampsia. J Endocrinol Invest. 2010;33(9):629–632.
  • Arikan D, Ozkaya M, Adali E, et al. Plasma lipocalin-2 levels in pregnant women with pre-eclampsia, and their relation with severity of disease. J Matern Fetal Neonatal Med. 2011;24(2):291–296.
  • Kim SM, Park JS, Norwitz ER, et al. Circulating levels of neutrophil gelatinase-associated lipocalin (NGAL) correlate with the presence and severity of preeclampsia. Reprod Sci. 2013;20(9):1083–1089.
  • Simonazzi G, Capelli I, Curti A, et al. Serum and urinary neutrophil gelatinase-associated lipocalin monitoring in normal pregnancy versus pregnancies complicated by pre-eclampsia. In Vivo. 2015;29(1):117–121.
  • Cui L, Shu C, Liu Z, et al. Serum protein marker panel for predicting preeclampsia. Pregnancy Hypertens. 2018;14:279–285.
  • Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
  • Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160.
  • Higgins J, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.2. London (UK): The Cochrane Collaboration; 2021. Available from: www.training.cochrane.org/handbook.
  • Schmitz EM, Langelaan ML, de Groot MJ, et al. Trimester-specific reference intervals for cystatin C and neutrophil gelatinase-associated lipocalin during pregnancy. Ann Clin Biochem. 2022;59(3):199–204.
  • Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: OHRI; 2010. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
  • Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. London (UK): The Cochrane Collaboration; 2011. Available from: www.cochranehandbook.org
  • Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
  • ACOG. ACOG practice bulletin no. 202: gestational hypertension and preeclampsia. Obstet Gynecol. 2019;133(1):1.
  • Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
  • Yin X, Huo Y, Liu L, et al. Serum levels and placental expression of NGAL in gestational diabetes mellitus. Int J Endocrinol. 2020;2020:8760563.
  • Zhang C, Zhang DD, Feng YM, et al. Relationship between morning peak phenomenon and early renal injury NGAL in H-type hypertension. Blood Press. 2022;31(1):200–206.
  • Sivalingam Z, Erik Magnusson N, Grove EL, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and cardiovascular events in patients with stable coronary artery disease. Scand J Clin Lab Invest. 2018;78(6):470–476.
  • Melchiorre K, Giorgione V, Thilaganathan B. The placenta and preeclampsia: villain or victim? Am J Obstet Gynecol. 2022;226(2S):S954–S962.
  • Kutasy B, Gosemann JH, Duess JW, et al. Increased trophoblastic apoptosis mediated by neutrophil gelatinase-associated lipocalin (NGAL) activation in the nitrofen model of congenital diaphragmatic hernia. Pediatr Surg Int. 2013;29(1):25–31.
  • Raguema N, Moustadraf S, Bertagnolli M. Immune and apoptosis mechanisms regulating placental development and vascularization in preeclampsia. Front Physiol. 2020;11:98.
  • Kobara H, Miyamoto T, Suzuki A, et al. Lipocalin2 enhances the matrix metalloproteinase-9 activity and invasion of extravillous trophoblasts under hypoxia. Placenta. 2013;34(11):1036–1043.
  • Barnett AM, Babcock MC, Watso JC, et al. High dietary salt intake increases urinary NGAL excretion and creatinine clearance in healthy young adults. Am J Physiol Renal Physiol. 2022;322(4):F392–F402.
  • Eilenberg W, Stojkovic S, Kaider A, et al. NGAL and MMP-9/NGAL as biomarkers of plaque vulnerability and targets of statins in patients with carotid atherosclerosis. Clin Chem Lab Med. 2017;56(1):147–156.
  • Tadesse S, Luo G, Park JS, et al. Intra-amniotic infection upregulates neutrophil gelatinase-associated lipocalin (NGAL) expression at the maternal-fetal interface at term: implications for infection-related preterm birth. Reprod Sci. 2011;18(8):713–722.
  • Vajrychova M, Kacerovsky M, Tambor V, et al. Microbial invasion and histological chorioamnionitis upregulate neutrophil-gelatinase associated lipocalin in preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med. 2016;29(1):12–21.
  • Eirini Papathanasiou A, Malamitsi-Puchner A, Gavrili S, et al. Perinatal lipocalin-2 profile at the extremes of fetal growth. J Matern Fetal Neonatal Med. 2021;34(13):2166–2172.